Key result
Timolol maintained a long-term survival benefit up to 72 months after acute myocardial infarction, with a cumulated mortality rate of 26.4% compared to 32.3% with placebo (P=0.0028).
Why the study?
Does timolol reduce mortality in patients after acute myocardial infarction?
Population
1,884 patients after acute myocardial infarction
Comparison
Timolol initially for up to 33 months, with the… vs Placebo initially, with the majority continuing…
Design
RCT, randomly assigned, double-blind initially, followed by open-label extension
Follow-up
up to 72 months
Loading...
Supports prolonged timolol use post-MI; extends early survival benefit to 72 months in RCT evidence.
RCT (n=1,884)
Double-blind
randomized
Yes
Does timolol reduce mortality in patients after acute myocardial infarction?
Absolute Event Rate: 26.4% vs 32.3%
p-value: p=0.0028
The early mortality benefit of timolol after acute myocardial infarction is maintained for at least six years.
A 1985 study conducted an RCT in Acute Myocardial Infarction (n=1,884). Timolol vs. Placebo was evaluated on Cumulated mortality (p=0.0028). Timolol maintained a long-term survival benefit up to 72 months after acute myocardial infarction, with a cumulated mortality rate of 26.4% compared to 32.3% with placebo (P=0.0028).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: